Nicotine effects on body weight: a regulatory perspective

Tobacco smoke exposure induces nicotine dependence in rats

RATIONALE

Tobacco smoke contains nicotine and many other compounds that act in concert on the brain reward system. Therefore, animal models are needed that allow the investigation of chronic exposure to the full spectrum of tobacco smoke constituents.

OBJECTIVES

The aim of these studies was to investigate if exposure to tobacco smoke leads to nicotine dependence in rats.

METHODS

The intracranial self-stimulation procedure was used to assess the negative affective aspects of nicotine withdrawal. Somatic signs were recorded from a checklist of nicotine abstinence signs. Nicotine self-administration sessions were conducted to investigate if tobacco smoke exposure affects the motivation to self-administer nicotine. Nicotinic receptor autoradiography was used to investigate if exposure to tobacco smoke affects central alpha7 nicotinic acetylcholine receptor (nAChR) and non-alpha7 nAChR levels (primarily alpha4beta2 nAChRs).

RESULTS

The nAChR antagonist mecamylamine dose-dependently elevated the brain reward thresholds of the rats exposed to tobacco smoke and did not affect the brain reward thresholds of the untreated control rats. Furthermore, mecamylamine induced more somatic withdrawal signs in the smoke-exposed rats than in the control rats. Nicotine self-administration was decreased 1 day after the last tobacco smoke exposure sessions and was returned to control levels 5 days later. Tobacco smoke exposure increased the alpha7 nAChR density in the CA2/3 area and the stratum oriens and increased the non-alpha7 nAChR density in the dentate gyrus.

CONCLUSION

Tobacco smoke exposure leads to nicotine dependence as indicated by precipitated affective and somatic withdrawal signs and induces an upregulation of nAChRs in the hippocampus.

The effects of chronic nicotine on meal patterns, food intake, metabolism and body weight of male rats

It is unclear what contribution food intake and metabolism have in causing weight loss after administering a dose of nicotine equivalent to smoking one to three packs of cigarettes per day because previous studies have been of a very short duration. To address this question, male Sprague Dawley rats were housed in computerized food intake modules and fed 45 mg pellets: Group 1 [nicotine injected with 1.4 mg/kg/day (free base), fed ad libitum]; and Group 2 [saline injected and pair-fed by computer with Group 2]; and Group 3 [saline injected (i.p.), fed ad libitum]. The rats received 4 equally spaced injections over the dark phase. Treatment consisted of: Phase 1 (nicotine or saline for 14 days), Phase 2 (all rats saline for 8 days and Phase 3 (pair-fed group "unyoked" for 6 days)). Nicotine inhibited food intake over the first 6 days. On termination of nicotine, there was no compensatory hyperphagia in either Groups 1 or 2; and their body weight was reduced starting on day 5 until day 28. In another study, rats were housed in an indirect calorimetry system. Saline or nicotine was injected for 14 days, as noted above; then all rats were injected with saline for 4 days and then no injections for 10 days to follow changes in body weight. Energy expenditure (Kcal/Kg(0.75)) was measured for 18 days. Nicotine significantly reduced food intake on 7 of 14 days of nicotine injections. The body weight of the nicotine injected rats was significantly reduced starting on day 3 until day 25. There were no differences in energy expenditures of the groups, which suggested that a decrease in food intake and not an increase in metabolism was the reason the rats lost weight after administering nicotine.

Body energy homeostasis

Evidence for the regulation of body energy is reviewed from the homeostatic perspective of Claude Bernard and Walter Cannon. The complementary roles of food intake and energy expenditure in the maintenance and defense of energy balance are considered. Particular attention is paid to the roles adjustments in energy expenditure play in this process and to recent investigations identifying their metabolic underpinnings. This is followed by a consideration of the many newly identified signals of body energy status and the pathways and feedback loops they utilize to inform the central regulating system. Finally, various naturally occurring and experimentally induced alterations in the regulated level of body energy are described and discussed. It is concluded that, though early investigators did not expressly consider energy a regulated feature of the milieu interieur, more recent research has provided a sound basis for judging the regulation of body energy to be another homeostatic process.

Treating tobacco use and dependence in clinical practice

Physicians are in a unique position to advise smokers to quit by the ability to integrate the various aspects of nicotine dependence. This review provides an overview of the intervention strategies for smokers presented in a primary care setting. The strategies that are used for smoking cessation counselling differ according to the patient's readiness to quit. For smokers who do not intend to give up smoking, physicians should inform about tobacco use and the benefits of cessation. For smokers who are dissonant, physicians should use motivational strategies, such as discussing the barriers to successful cessation and their solutions. For smokers who are ready to quit, the physician should show strong support, help set a date to quit, prescribe pharmaceutical therapies for nicotine dependence, such as nicotine replacement therapy (i.e., gum, transdermal patch, nasal spray, mouth inhaler, lozenges, and micro and sublingual tablets) and/or bupropion (an atypical antidepressant thought to work by blocking the neural re-uptake of dopamine and/or noradrenaline), with instructions for use, and suggest behavioural strategies to prevent relapse. The efficacy of all of these pharmacotherapies is comparable, roughly doubling the cessation rates over control conditions.

Systemic nicotine alters whole-body fat utilization in female rats

Cigarette smoking produces weight suppression in humans that often rebounds following smoking cessation. Nicotine (NIC) administration produces similar effects in rats. While changes in food intake are thought to account for some of the body weight changes, few reports have investigated how NIC affects whole-body metabolism. In the present study, measures of respiratory quotient (RQ) and energy expenditure (EE) were used to investigate metabolic changes that may contribute to NIC's effects on body weight. Female rats (n=46) were implanted for 14 days with subcutaneous Alzet minipumps containing NIC (6 mg/kg/day) or its vehicle. One-hour metabolic test sessions occurred four times: 2 and 12 days after pump implant and 2 and 8 days after pump removal. NIC initially suppressed body weight gain, followed by steady recovery that was briefly exaggerated after withdrawing NIC. Daily food intake was acutely suppressed by NIC and acutely potentiated after NIC cessation. RQ, but not EE, was suppressed by NIC 2 days after pump implant indicating increased fat utilization. Conversely, RQ was increased 2 days after pump removal signaling increased fat storage. These findings indicate that acute changes in whole-body metabolism may contribute to the weight modulating effects of NIC.

Intermittent nicotine administration modulates food intake in rats by acting on nicotine receptors localized to the brainstem

Previous studies have shown nicotine (NIC) administration leads to decreased food intake, while other investigations have reported that NIC stimulates c-Fos expression in the brainstem. Whether there is a causal relationship between NIC effects on ingestion and its effect on brainstem neurons is uncertain, however we hypothesized that blocking NIC action in the brainstem would prevent, to some extent, the hypophagic effects of NIC. In the present study, cannulas were placed in the fourth ventricle of rats. A dose of NIC or saline was injected i.p. in four equal injections during the dark phase for four days. At the start of the second day of injections the NIC receptor antagonist mecamylamine (MEC) or artificial cerebrospinal fluid (a-CSF) was infused intracerebroventricularly (i.c.v.). Thus, four experimental groups were examined: a-CSF + SAL; a-CSF + NIC; MEC + SAL; MEC + NIC. Meal patterns were recorded using a computerized system and water intake and body weight were measured daily. Peripheral NIC injections suppressed food intake by decreasing meal size, whereas infusion of the NIC receptor antagonist MEC (4 microg) into the fourth ventricle blocked the NIC suppression of food intake. Moreover, the MEC effect was due primarily to an increase in dark phase meal size, which suggests neurons localized to the brainstem transmit NIC signals that regulate feeding behavior by affecting meal size.

Motivational Influences on Cigarette Smoking

Cigarette smoking is a leading cause of mortality and morbidity and a particularly common and intractable addictive disorder. Research shows that nicotine is a sine qua non of tobacco addiction and that it produces the hallmark effects of addictive drugs: sensitization, tolerance, physical dependence, and euphoria/elation. Research on the development of smoking reveals that although smoking prevalence has declined from a peak in the mid-1990s, close to 30% of twelfth graders still smoke. Smoking in adolescents is related to development of physical dependence, ethnicity, impulsivity, affective disorder, and peer influences. However, which of these exerts the greatest causal effects is unknown, and their influence no doubt varies across individuals and across development. Once dependence on tobacco smoking is established, evidence suggests that tobacco motivation is strongly influenced by a reduction in withdrawal symptoms, an expectation of stress reduction, and conditioned reinforcement. Nicotine motivation may also be influenced by modulation in stimulus incentive value.

Effect of i.c.v. infusion of the alpha-MSH agonist MTII on meal patterns in male rats following nicotine withdrawal

The present study explored the role of endogenous alpha-MSH in the alteration of meal patterns induced by nicotine (NIC) withdrawal. Male Sprague Dawley rats bearing third ventricle cannulas were placed in computerized food intake monitors. On days 1-21, the rats were given 4 mg/kg/day of NIC or saline (SAL) in four equal i.p. doses during the dark period. NIC suppressed (P < 0.05) food intake only during the first week. The normalization of food intake occurred when the reduced meal size of the NIC injected rats was countered by an increase in meal number. Despite the normalization of 24-h food intake, body weight in NIC rats was decreased (P < 0.05) for 21 days. On day 22, the rats were divided into 4 groups (n's = 7-8 each) and injected into the third ventricle with various doses of the alpha-MSH agonist MTII or artificial cerebrospinal fluid (aCSF): SAL + aCSF, SAL + MTII, NIC + aCSF, NIC + MTII. Infusion of MTII (30 ng/rat) suppressed (P < 0.01) dark phase food intake in both groups, but the NIC + MTII group ate (P < 0.05) more than the SAL + MTII group. Meal number during the dark phase was suppressed by MTII, but the NIC + MTII group took significantly more meals that the SAL + MTII group. Infusion of MTII suppressed meal size in SAL and NIC treated rats, but this effect was attenuated in NIC treated rats. All meal parameters normalized by the day after i.c.v. infusion. These data indicate that NIC treatment differentially affects the neural controls of meal number and meal size and attenuates the suppression by MTII of meal number and meal size.

Nicotine and its withdrawal modify dorsal raphe 8-hydroxy-2-(di-n-propylamino) tetralin feeding

Nicotine (NIC) and its withdrawal modify dorsal raphe (DR) serotonin (5-HT) neurotransmission in ways that may contribute to the body weight loss vs. gain associated with cigarette smoking vs. cessation, respectively. Modifications in feeding to DR infusions of the 5-HT-1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), were used to characterize these potential relationships in the DR-5-HT system during NIC administration vs. withdrawal. Two groups of female rats (total N=45) were implanted for 14 days with subcutaneous Alzet minipumps containing NIC (6 mg/kg/day) or saline. Mid-light cycle (1300-1500 h) 8-OH-DPAT feeding tests occurred three times: (1) 2 days after pump implant, (2) 12 days after pump implant, and (3) 2 days after pump removal. Each feeding test consisted of a 1-h measure of pre-feeding, then a 1-h measure of feeding after DR injection of 8-OH-DPAT (0.6 nmol) or 0.4 microl saline. NIC administration produced acute hypophagia, weight loss, and attenuated 8-OH-DPAT-induced feeding. NIC withdrawal produced acute hyperphagia, weight gain, and a transient increase in 8-OH-DPAT feeding. These findings provide behavioral evidence that systemic NIC modifies the DR 5-HT system in ways that may contribute to NIC's ability to alter feeding and body weight.

Meal patterns in male rats during and after intermittent nicotine administration

Continuous administration of nicotine (NIC) reduces food intake (FI) and body weight (BW), whereas rebound eating and BW gain occur after NIC cessation. However, generalizations derived from prior studies on meal patterns in rats using continuous 24-h NIC administration are limited, because human smokers use NIC intermittently during their active period. In the present study, computerized meal pattern analyses (MPA) were conducted for adult male rats treated for 14 days with either saline or 2 or 4 mg/kg/day of NIC spread over five equal amounts during the dark phase. MPA analyses continued for 14 days after cessation of NIC. Only the 4 mg/kg/day NIC dose caused consistent changes in meal patterns and only that dose is reported herein. Dark period FI was reduced, whereas light period FI was unchanged in the NIC-treated group; thus, there was no rebound eating during the 12-h nontreatment phase. MPA analyses revealed the FI reduction on Day 1 of NIC administration was caused by a persistent decrease in dark phase meal size. On Day 5 of NIC, the rats compensated by significantly increasing the number of meals they took, which tended to normalize dark phase FI. Congruently, dark phase intermeal interval was decreased. Importantly, these changes in meal patterns persisted for 2 weeks after termination of NIC. Upon NIC cessation, the NIC group had a transient elevated FI. The NIC-treated group's BW was significantly suppressed by Day 6 of NIC and after stoppage these rats slowly, but incompletely, regained lost BW over the next 14 days. These results document that administration of NIC during the dark phase resulted in a reorganization of the microstructure of FI in male rats and that long-lasting alterations in the microstructure of FI (e.g., meal size and meal number) were noted for up to 2 weeks after cessation of NIC. These results differ from studies in which NIC was given continuously 24-h/day and indicate that dark phase NIC administration in rats may represent an appropriate model to study the impact of NIC on meal patterns.

Pharmacological approaches for the treatment of obesity

The high incidence of obesity, its multifactorial nature, the complexity and lack of knowledge of the bodyweight control system, and the scarcity of adequate therapeutics have fuelled anti-obesity drug development during a considerable number of years. Irrespective of the efforts invested by researchers and companies, few products have reached a minimum level of effectiveness, and even fewer are available in medical practice. As a consequence of anti-obesity research, our knowledge of the bodyweight control system increased but, despite this, the pharmacological approaches to the treatment of obesity have not resulted yet in effective drugs. This review provides a panoramic of the multiple different approaches developed to obtain workable drugs. These approaches, however, rely in only four main lines of action: control of energy intake, mainly through modification of appetite;control of energy expenditure, essentially through the increase of thermogenesis;control of the availability of substrates to cells and tissues through hormonal and other metabolic factors controlling the fate of the available energy substrates; andcontrol of fat reserves through modulation of lipogenesis and lipolysis in white adipose tissue. A large proportion of current research is centred on neuropeptidic control of appetite, followed by the development of drugs controlling thermogenic mechanisms and analysis of the factors controlling adipocyte growth and fat storage. The adipocyte is also a fundamental source of metabolic signals, signals that can be intercepted, modulated and used to force the brain to adjust the mass of fat with the physiological means available. The large variety of different approaches used in the search for effective anti-obesity drugs show both the deep involvement of researchers on this field and the large amount of resources devoted to this problem by pharmaceutical companies. Future trends in anti-obesity drug research follow closely the approaches outlined; however, the increasing mass of information on the molecular basis of bodyweight control and obesity will in the end prevail in our search for effective and harmless anti-obesity drugs.

Effects of nicotine and mecamylamine on rat dorsal raphe neurons

This study investigates the hypothesis that serotonin mediates certain nicotine effects, such as mood improvement and the suppression of the ponto-geniculo-occipital spikes of rapid eye movement sleep. The influence of nicotine (10-300 microM) on the firing rate of dorsal raphe neurons and on serotonin release was therefore, studied in rat midbrain slices. Nicotine increased the firing rate, 10-90%, in 67.5% recorded neurons and decreased it, 8-100%, in the remaining 32.5%. Serotonin release increased 2-7 times after nicotine administration, regardless of firing frequency, but the absolute value of serotonin release was 3 times higher during the decreases than during the increases in firing rate. Mecamylamine (1-20 microM) transiently stimulated the dorsal raphe neurons and competitively antagonized the nicotine-induced serotonin release. The results support the working hypothesis and additionally show that mecamylamine also stimulates dorsal raphe neurons.

Body weight set-points: determination and adjustment

It is proposed that body weight, like body water and body temperature, is physiologically regulated. In the case of body weight, coordinated adjustments in both the intake and expenditure of energy serve to stabilize the weights of individuals at a specified level and to resist their displacement from this level. Obese individuals also display these behavioral and metabolic adjustments to weight perturbations and thus appear to actively resist efforts to reduce their weight from the elevated levels they ordinarily display. Experimental studies of genetically transmitted and diet-induced forms of obesity in animals similarly suggest a view of obesity as a condition of body energy regulation at an elevated set-point. An individual's set-point for regulated body weight is apparently adjustable, shifting over a lifespan in conjunction with naturally occurring but still unspecified physiologic changes. Experimentally, the set-point for body weight can be adjusted by manipulation of specific hypothalamic sites. Lesions of the lateral hypothalamus, for example, cause a chronic reduction in the level at which laboratory animals regulate body weight. It thus appears that hypothalamic mechanisms play a primary role in setting the level at which individuals regulate body weight, and it is likely that the genetic, dietary and other lifespan influences on body weight are expressed through these mechanisms.

A prospective study of the effects of changes in smoking habits on blood count, serum lipids and lipoproteins, body weight and blood pressure in occupationally active men. The Israeli CORDIS Study

In cross-sectional studies, significant differences in cardiovascular disease risk factors have been observed between smokers and non-smokers. The aim of this study was to examine the effects of smoking initiation and cessation on these factors in a population-based prospective study. 987 male employees in Israeli industry underwent health screening in the CORDIS study and were re-examined an average of two and a half years later. We examined the associations between smoking initiation and cessation and changes in blood count, serum lipids and lipoproteins, body weight and blood pressure. After adjusting for potential confounders, smoking cessation was associated with significant decreases in leukocyte count, hemoglobin and hematocrit whereas smoking initiation resulted in increased leukocyte count. There were moderate, non-significant increases in both serum HDL cholesterol (HDL-C) and LDL-C, and a slight decrease in serum triglycerides. Blood pressure remained essentially unchanged, despite the fact that smoking cessation resulted in a significant weight increase and smoking initiation in a significant decline in weight. These findings demonstrate that changes in smoking habits result in fairly rapid changes in blood count and body weight, but have much smaller effects on serum lipids and blood pressure.

Effects of chronic phenylpropanolamine infusion and termination on body weight, food consumption and water consumption in rats

The present study determined the effect of chronic PPA infusion and withdrawal on weight regulation. Male Sprague-Dawley rats received PPA (0, 90 or 180 mg/kg) via miniosmotic pumps for 2 weeks. Body weight and food and water consumption were measured daily before, during, and for 2 weeks after PPA infusion. Additionally, body weight was measured once 6 weeks after the last day of drug administration. PPA infusion produced dose-dependent reductions in body weight and food consumption throughout drug administration. During the first week of PPA termination, food consumption returned to control levels; however, body weights of drug-treated animals remained below those of controls throughout the 6-week post-drug period. PPA depressed water intake during the first week of drug administration, but tolerance to this effect developed by the second week of administration. These results suggest chronic PPA infusion produces persistent appetite suppression and weight loss and that discontinuation of PPA does not result in hyperphagia or rapid weight gain. These findings may have clinical significance for the many individuals who wish to lose weight but have difficulty reducing intake without pharmacologic assistance.

Effects of systemic nicotine on serotonin release in rat brain

We used in vivo microdialysis to examine the acute effects of systemically administered nicotine (0.8-8.0 mg/kg, s.c.) on extracellular levels of serotonin (5-HT) in the frontal cortex of awake rats and animals anesthetized with chloralose/urethane. In anesthetized animals, 5-HT efflux was elevated during the initial 15 min after nicotine administration (2-8 mg/kg), but then returned to baseline values. All of the effective nicotine doses also lowered and then raised blood pressure in these animals. However, other drugs which raised (methoxamine, 0.07 mg/kg, i.v.) or lowered (mecamylamine, 5 mg/kg, i.p.) blood pressure without directly activating nicotinic receptors failed to alter 5-HT release. Moreover, pretreatment with a centrally active dose of mecamylamine, a known nicotinic antagonist, blocked the effects of nicotine (4 mg/kg) on 5-HT release. For studies on awake rats the perfusion fluid also contained fluoxetine, since basal 5-HT levels were barely detectable without this uptake blocker. In such animals, 1.6 mg/kg of nicotine significantly increased 5-HT release, an effect apparent in the initial 20 min after treatment and persisting for at least 2 h. These observations demonstrate that systemically administered nicotine increases frontocortical 5-HT release, that this effect is independent of the cardiovascular responses to the drug, and that it probably results from the activation of previously described nicotinic receptors on raphe neurons. The present findings are consistent with the hypothesis that the appetitive and mood disturbances associated with nicotine withdrawal may be mediated by diminished serotoninergic transmission.